China Pharma (CPHI) vs GridAI Technologies (GRDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GridAI Technologies (GRDX) has outperformed China Pharma (CPHI) over the past year, gaining 20.0% versus a loss of 51.8%. Over five years, CPHI leads with a -99.7% price change compared with -100.0% for GRDX. China Pharma is the larger company by market cap ($41.3 million vs $34.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPHI | GRDX |
|---|---|---|
| Share price | $0.96 | $4.80 |
| Market cap | $41.30M | $34.23M |
| 1-day change | +12.94% | +16.50% |
| YTD return | -20.66% | +3.00% |
| 1-year return | -51.76% | +20.00% |
| 5-year return | -99.65% | -99.99% |
| EPS (TTM) | $-0.42 | $-5.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.19 | $6.93 |
| 52-week low | $0.38 | $1.87 |
| Distance from 52-week high | -95.00% | -30.73% |
| Average volume | 5.81M | 104.68K |
| Shares outstanding | 43.02M | 7.13M |
| Employees | 215 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRDX has outperformed CPHI by 71.8 percentage points over the past year.
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees
About GridAI Technologies
GRDX stock →GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency.
Health Care · Biotechnology: Pharmaceutical Preparations
CPHI vs GRDX FAQ
Which is bigger, China Pharma or GridAI Technologies?
China Pharma (CPHI) is larger, with a market capitalization of $41.30M compared with $34.23M for GridAI Technologies (GRDX).
Which stock has performed better over the past year, CPHI or GRDX?
GRDX returned +20.00% over the past 12 months, compared with -51.76% for CPHI (price return, excluding dividends). Past performance does not predict future results.
Are China Pharma and GridAI Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.